Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban Absorption in Cervical Spinal Cord Injury
NCT02970773Phase 4Withdrawn
- Sponsor
- Swiss Paraplegic Research
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban in thromboembolism, sponsored by Swiss Paraplegic Research. Primary endpoint: rivaroxaban plasma level at 24 hours. Planned start Dec 2017; status: withdrawn.
02
Drugs
rivaroxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02970773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970773.